## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

	5244- ip)		Line) X	Form filed by One Repo Form filed by More than Person	0	
	5244-		I (	Form filed by One Repo	rting Person	
P		4. If Amendment, Date of Original Filed (Month/Day/Year)		vidual or Joint/Group Filing (Check Applicab Form filed by One Reporting Person		
(Last) (First) (M 2190 PARKWAY LAKE DRIVE		3. Date of Earliest Transaction (Month/Day/Year) 01/30/2009		SR VP - CMO		
1. Name and Address of Reporting Person <sup>*</sup> Sheridan William P		2. Issuer Name and Ticker or Trading Symbol <u>BIOCRYST PHARMACEUTICALS INC</u> [ BCRX ]		ationship of Reporting Pers ( all applicable) Director Officer (give title below)	son(s) to Issuer 10% Owner Other (specify below)	

### 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 3. 5. Amount of 6. Ownership 7. Nature Transaction Date Execution Date. Securities Form: Direct of Indirect (Month/Day/Year) Code (Instr. 8) (D) or Indirect (I) (Instr. 4) Beneficial Ownership if any 5) Beneficially Owned Following (Month/Day/Year) Reported (Instr. 4) (A) or (D) Transaction(s) Code v Amount Price (Instr. 3 and 4) Common Stock 01/30/2009 Р 3,000<sup>(1)</sup> Α \$1.615 3,000 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Shares were purchased under ESPP

### /s/ Michael Richardson, by power of attorney

02/03/2009

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.